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Risks of getting HIV infections and STIs when traveling to
Latin America
G. Lopardo
FUNCEI, Buenos Aires, Argentina
Sexually transmitted infections (STIs) including HIV infec-
tion are responsible for a variety of acute and chronic
medical problems. Travel may interfere with human sexual
practices by splitting ﬁxed sexual partnerships and remov-
ing social taboos. Increased sexual promiscuity and casual
sexual relationships are likely to occur during travel because
people have the opportunity to escape from standard behav-
iors.
In Latin-American countries (LAC) the prevalence of STIs
is extremely high. Syphilis has a variable prevalence rate
among sex workers in LAC, ranging from 7% in Panama to 29%
in Santos, Brazil. The same applies for gonococcal infections
and other STIs. Resistance rates of Neisseria gonorrhoeae to
different antibiotics vary according to different countries.
Regarding chronic hepatitis B, seroprevalence for different
LAC varies between high-endemicity regions like the Ama-
zon basin, and low and intermediate areas like Argentina
and South Brazil, respectively, determining different risks of
exposure to travelers. There are no vaccines for STIs, with
the exception of those for HBV. It is estimated that in the
Latin American area there are 2 million people living with
HIV and AIDS. Brazil accounts accounts for more than 40%
of total infections. In some Brazilian cities, more than 60%
of drug users are HIV positive. The most severe epidemics
are found in smaller countries such as Belize, Guyana and
Suriname, with HIV prevalence rates of 2.1%, 2.5% and 2.4%
respectively. The majority of countries in the region have
prevalence rates of less than 1%, but the prevalence among
speciﬁc groups, such as men who have sex with men and sex
workers, is often very high. Primary resistance rates of HIV
vary according to the visited area.
Screening of asymptomatic travelers who had casual sex
abroad should be encouraged.
doi:10.1016/j.ijid.2010.02.1868
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The WHO global plan to map and combat neglected trop-
ical diseases
L. SavioliWHO, Geneva, Switzerland
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eglected tropical diseases in Latin America and the
aribbean: Prospects for Control and Elimination
. Ault
PAHO, Washington, DC
In Latin America and the Caribbean, 180 million people
ive in poverty, and carry most of the burden of neglected
ropical diseases (NTDs) like soil-transmitted helminthia-
is, schistosomiasis, Chagas disease, lymphatic ﬁlariasis,
nchocerciasis, leishmaniasis, trachoma, rabies, and other
nfections of poverty like neonatal tetanus and congenital
yphilis.
These neglected diseases are often restricted to the rural
nd urban poor and vulnerable and excluded groups like
omen and children, and indigenous communities. They
dversely affect school attendance, children’s physical and
ognitive development, pregnancy outcome, labor produc-
ivity, and/or income-earning capacity, and create social
tigma.
A comprehensive integrated approach with access to
iagnostic and treatment tools and an agenda to address
heir social determinants. Political commitment from mul-
iple sectors is needed to ensure resource availability
nd international support. To facilitate development of
his commitment, the Pan American Health Organization
PAHO)/WHO with its partners have recently taken several
ajor actions. Ten neglected diseases have been mapped
y PAHO in 14 countries for ‘‘hot spots’’. PAHO partnered
ith the Inter-American Development Bank and the Global
etwork for Neglected Tropical Diseases to develop a new
egional Fund for control and elimination of NTDs and other
nfectious diseases of poverty. PAHO’s Directing Council
assed Resolution CD49.R19 (2009) in which Member States
ommitted by 2015 to eliminate or reduce those neglected
iseases for which adequate tools and strategies exist, to
evels in which they are no longer public health problems.
PAHO and partners will complete mapping of the distribu-
ion and overlap of neglected diseases in the Region; develop
vidence-based guidelines and demonstration projects for
ntegrated control; develop models to address social
eterminants; strengthen, scale up and intensify existing
rograms of control and elimination through technical coop-
ration; and plan for certiﬁcation of elimination of diseases
ike onchocerciasis and lymphatic ﬁlariasis which are close
o elimination in the Region.
oi:10.1016/j.ijid.2010.02.1870
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hagas disease research: Advances and needs
. Yadon
Pan American Health Organization, Washington DC, DC, USA
American trypanosomiasis — a zoonotic disease caused
y Trypanosoma cruzi (Protozoa, Kinetoplastida) — is trans-
itted to humans by blood-sucking triatomine bugs, blood
ransfusion and congenital transmission. Successful regional
ector control programs based on the residual application
f insecticide and improved screening of blood donors have
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chieved important reductions in the incidence of Chagas
isease in many Latin American countries. However, this
pproach has been ineffective in some geographic areas
uch as the Gran Chaco. As a result, the development of
ffective new tools in these areas to prevent house rein-
estation by triatomine bugs is a high research priority. No
ess important is the need of innovative approaches includ-
ng those generated from genomics to improve upon existing
iagnostic tests and to develop new parasitological tests
or the early diagnosis of congenital infection in the new-
orn and in immunocompromised patients, as well as for
he assessment of treatment response (PCR; antigenemia,
ecombinant antigens,synthetic peptides etc.). There is also
pressing need of developing new anti-T. cruzi agents with
igh activity in both the acute and chronic phases, and epi-
emiological methods that me may be used to estimate the
revalence of infection, subclinical disease and treatment
eeds in endemic and non-endemic countries.
oi:10.1016/j.ijid.2010.02.1871
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ntegrated control of neglected tropical diseases in Africa
.J. Bockarie
Centre for Neglected Tropical Diseases, Liverpool, United
ingdom
Neglected tropical diseases (NTD) are the ‘other dis-
ases’ of Millennium Development Goal 6 that have received
ittle attention from policy-makers and politicians who
ver focus on HIV, tuberculosis and malaria. They include
any medically diverse diseases that are strongly associ-
ted with poverty. NTDs include bacterial, viral, protozoan
nd helminth infections that have plagued humanity since
ntiquity. Globally, over one billion people suffer from one
r more NTDs and about 500,000 people die from them every
ear.
Neglected Tropical Diseases are widespread in Africa due,
n part, to the low socio-economic status of rural popula-
ions. Many countries are endemic with of 5 or more NTDs
ncluding schistosomiasis, soil-transmitted helminths (STH),
ymphatic ﬁlariasis, onchocerciasis and trachoma, as well
s zoonotic disease such as human African trypanosomiasis,
abies, tick borne relapsing fevers, echinococcus (hydatid),
aeniosis (cysticercosis), brucellosis and plague, with a large
art of the population at risk of co-infection with 2 or more
f these diseases.
Fortunately, control strategies as well as diagnostic tools
nd the availability of safe and effective drugs exist for the
TDs responsible for the greatest burden in Africa: lym-
hatic ﬁlariasis, onchocerciasis, STH and schistosomiasis.
he World Health Organization has developed a strategy,
reventive Chemotherapy and Transmission Control (PCT),
hich is geared towards the implementation of large-scale
ass drug administration. The objective of PCT is to pro-
ide national programmes with technical guidelines that
mphasize a coordinated, cost-effective approach to the
mplementation of national elimination and control activ-
ties where preventive chemotherapy is the main tool, i.e.
egular anthelminthic drug administration to all people at
isk of morbidity due to helminthic diseases, starting early
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n life. The availability of rapid diagnostic tools and dona-
ions of several drugs from pharmaceutical companies, and
he reduced price of other essential antihelminthic drugs
as catalysed the rapid expansion of chemotherapy-based
ontrol programmes for NTDs. The main challenges to PTC
n Africa include poor health service infrastructure in post
onﬂict countries and cost-effective approaches for inte-
rating the individual vertical programmes targeting speciﬁc
iseases.
oi:10.1016/j.ijid.2010.02.1872
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nusual clinical proﬁle of Dengue Infection in patients
ttending a tertiary care teaching hospital in north India
. Agarwal ∗, G. Kapoor, S. Srivastava, K.P. Singh, R. Kumar,
. Jain
C S M Medical University, Lucknow, Uttar pradesh, India
Background: Major outbreaks of dengue virus have been
eported from many parts of North India including Luc-
now, at regular intervals since 1996. We have carried out a
etailed investigation of the Dengue cases occurring in year
008.
Methods: Clinically suspected patients attending Pedi-
trics and Medicine outpatient or inpatient Departments and
eferred to Microbiology Department for serological diagno-
is of dengue, were prospectively enrolled after obtaining
erbal consent. Detailed clinical history and examination
ndings were recorded in a pre designed questionnaire from
98 such patients between Jan 2008 to Dec 2008. Dengue
peciﬁc antibodies were detected using commercial Mac-
LISA kit (IVD, USA). Results of hematological and other
nvestigations were noted from medical records.
Results: Mean age of patients’ was10.25± 10.9 years and
28/398 were in pediatric age group (%12 yrs age). A total of
3.26% (212/398) patients were positive for dengue IgM and
3% of these were admitted patients. Male: Female ratio
as1.8:1 and ∼74% belonged to rural area. Overwhelming
ajority (92%) of dengue cases were seen between July
o November, which are the post monsoon months in this
art of world. Frequent clinical features included fever
100%) withmean duration of 14.07± 9.2 days, edema (50%),
ltered sensorium (39%), rash (31.84%). Mucosal bleeding,
epatomegaly and splenomegaly were present in 31.84%,
7.29% and 56.25% respectively. Thrombocytopenia (58.74%)
as common laboratory ﬁnding. Liver enzymes SGPT and
GOT were raised in 72.55% and 78.43% of positive cases,
espectively. Presentation varied between adults and pedi-
tric populations, while among adults, seizure (p = 0.029),
kin rash (p = 0.029), abdominal pain (p = 0.005) and hemo-
oncentration (PCV > 36; p = 0.063) were signiﬁcant ﬁndings;
owever in children, headache (p = 0.029), serum sodium
nd calcium levels (p = 0.022 and p = .0006) were signif-
cantly raised. Logistic Regression analysis found serum
GOT>40 U/L and presence of splenomegaly as independent
redictors for dengue infection. Only 3 cases met the WHO
riteria for dengue haemorrhagic fever (DHF), however clin-
cally ∼20% of the dengue positive cases were labelled and
